Form 8-K - Current report:
SEC Accession No. 0001193125-25-012329
Filing Date
2025-01-24
Accepted
2025-01-24 17:24:41
Documents
15
Period of Report
2025-01-24
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d920756d8k.htm   iXBRL 8-K 25765
2 EX-5.1 d920756dex51.htm EX-5.1 9408
6 GRAPHIC g920756g0124042029209.jpg GRAPHIC 2535
  Complete submission text file 0001193125-25-012329.txt   160466

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA imvt-20250124.xsd EX-101.SCH 2847
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE imvt-20250124_lab.xml EX-101.LAB 17235
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE imvt-20250124_pre.xml EX-101.PRE 10810
17 EXTRACTED XBRL INSTANCE DOCUMENT d920756d8k_htm.xml XML 3496
Mailing Address 320 WEST 37TH STREET NEW YORK NY 10018
Business Address 320 WEST 37TH STREET NEW YORK NY 10018 917-580-3099
Immunovant, Inc. (Filer) CIK: 0001764013 (see all company filings)

EIN.: 832771572 | State of Incorp.: DE | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-38906 | Film No.: 25555235
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)